Acute Kidney Injury in Patients With Liver CirrhosisNCT06343389
Acute Kidney Injury in Patients With Liver Cirrhosis
An observational study of Acute Kidney Injury in Patients With Liver Cirrhosis, run by Sohag University at 1 site in Egypt.
Trial summary
In our locality, limited studies have discussed AKI in patients with liver cirrhosis and its outcome, therefore we aim to highlight the incidence, patterns, risk factors, and outcomes of acute kidney injury in patients with liver cirrhosis at Sohag University Hospital. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Kidney Injury in Patients With Liver Cirrhosis
- What is being tested?
- serum creatinine
- How many people
- 180 participants
- Where
- 1 siteEgypt
- Study dates
- 6 Jul 2024to 15 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cirrhotic patients ( age more than 18 years old ) in Sohag University Hospital
Who may be able to join
- Cirrhotic patients ( age more than 18 years old ) in Sohag University Hospital
Who cannot join
- patients with known preexisting chronic kidney disease
- patients who had undergone renal transplantation
- malignancy
- pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study of Acute Kidney Injury in Patients With Liver Cirrhosis at Sohag University Hospital
In our locality, limited studies have discussed AKI in patients with liver cirrhosis and its outcome, therefore we aim to highlight the incidence, patterns, risk factors, and outcomes of acute kidney injury in patients with liver cirrhosis at Sohag University Hospital.
Read the detailed description
Acute kidney injury (AKI) is a common condition in patients with cirrhosis. It occurs in up to 50% of hospitalized patients with cirrhosis and in 58% of such patients in the intensive care unit. AKI is one of the key predictors for short-term mortality in patients with liver cirrhosis with mortality rates as high as 90%. There is a remarkable increase in length of hospital stay with high financial burden on patients with AKI.
In general, the three main causes of AKI are renal hypoperfusion (also referred to as prerenal AKI), which in most cases is due to hypovolemia; intrinsic, structural kidney injury; and postrenal injury due to urinary obstruction. A unique cause of AKI due to renal hypoperfusion in patients with cirrhosis is the hepatorenal syndrome (HRS), which is the result of renal vasoconstriction. Early identification and management of AKI may improve outcomes.
In our locality, limited studies have discussed AKI in patients with liver cirrhosis and its outcome, therefore we aim to highlight the incidence, patterns, risk factors, and outcomes of acute kidney injury in patients with liver cirrhosis.
- Being tested
- serum creatinine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
serum creatinineDiagnostic test
to detect patients with Acute kidney injury
| Study group | Role | What they receive |
|---|---|---|
| group A | Cirrhotic patients with Acute kidney injury Receives: Diagnostic Test: serum creatinine | |
| group B | Cirrhotic patients without Acute kidney injury Receives: Diagnostic Test: serum creatinine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of acute kidney injury in cirrhotic patients in Sohag University Hospital
Number of new cases of acute kidney injury (which will be diagnosed by either increase in serum creatinine ≥0.3 mg/dl within 48 hours; or, a percentage increase in serum creatinine ≥50% within the prior seven days) occurring in cirrhotic patients in Sohag University Hospital.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2024
- Study start6 Jul 2024
- Primary completion15 Oct 2024
- Study completion15 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Kidney Injury in Patients With Liver CirrhosisStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 180 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Shehab Ahmed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06343389
- Sponsor's protocol ID
- Soh-Med-24-03-14MS
- Status last verified
- Apr 2026
- First submitted
- 25 Mar 2024
- Last updated
- 15 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Acute Kidney Injury in Patients With Liver Cirrhosis at Sohag University Hospital
- ClinicalTrials.gov ID
- NCT06343389
- Acronym / sponsor ID
- Soh-Med-24-03-14MS
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 180 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 6 Jul 2024 (actual)
- Primary completion
- 15 Oct 2024 (actual)
- Study completion
- 15 Jul 2025 (actual)
- First posted
- 2 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In our locality, limited studies have discussed AKI in patients with liver cirrhosis and its outcome, therefore we aim to highlight the incidence, patterns, risk factors, and outcomes of acute kidney injury in patients with liver cirrhosis at Sohag University Hospital.
Detailed description
Acute kidney injury (AKI) is a common condition in patients with cirrhosis. It occurs in up to 50% of hospitalized patients with cirrhosis and in 58% of such patients in the intensive care unit. AKI is one of the key predictors for short-term mortality in patients with liver cirrhosis with mortality rates as high as 90%. There is a remarkable increase in length of hospital stay with high financial burden on patients with AKI.
In general, the three main causes of AKI are renal hypoperfusion (also referred to as prerenal AKI), which in most cases is due to hypovolemia; intrinsic, structural kidney injury; and postrenal injury due to urinary obstruction. A unique cause of AKI due to renal hypoperfusion in patients with cirrhosis is the hepatorenal syndrome (HRS), which is the result of renal vasoconstriction. Early identification and management of AKI may improve outcomes.
In our locality, limited studies have discussed AKI in patients with liver cirrhosis and its outcome, therefore we aim to highlight the incidence, patterns, risk factors, and outcomes of acute kidney injury in patients with liver cirrhosis.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| group A | – | Diagnostic Test: serum creatinineCirrhotic patients with Acute kidney injury |
| group B | – | Diagnostic Test: serum creatinineCirrhotic patients without Acute kidney injury |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cirrhotic patients ( age more than 18 years old ) in Sohag University Hospital
Key inclusion criteria (1 listed)
- Cirrhotic patients ( age more than 18 years old ) in Sohag University Hospital
Key exclusion criteria (4 listed)
- patients with known preexisting chronic kidney disease
- patients who had undergone renal transplantation
- malignancy
- pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| serum creatinineto detect patients with Acute kidney injury | Diagnostic test | group A, group B |
Primary outcome
Incidence of acute kidney injury in cirrhotic patients in Sohag University Hospital
Time frame: 1 year
Number of new cases of acute kidney injury (which will be diagnosed by either increase in serum creatinine ≥0.3 mg/dl within 48 hours; or, a percentage increase in serum creatinine ≥50% within the prior seven days) occurring in cirrhotic patients in Sohag University Hospital.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2026.
Related trials for Acute Kidney Injury in Patients With Liver Cirrhosis
Not yet recruitingObservational study
Predictors of Mortality in Cirrhotic Patients With Acute Kidney Injury
AKI in Cirrhosis
Not yet recruiting
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction
Liver Cirrhosis
RecruitingPhase 2
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
Acute Kidney Injury, Cirrhosis
Active, not recruitingEarly Phase 1
Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance
Septic Shock, Cirrhosis
Active, not recruitingPhase 2
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Hepatorenal Syndrome, Liver Cirrhosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Kidney Injury in Patients With Liver Cirrhosis, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of acute kidney injury in cirrhotic patients in Sohag University Hospital (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.